PFE Latest Headlines

Pfizer’s Real-World Breast Cancer Study Signals Strategic Push in HER2-Positive Market

at www.tipranks.com (Fri, 9-Jan 11:30 AM)

Pfizer inks licensing deal with Madrigal for MASH candidate

at seekingalpha.com (Fri, 9-Jan 8:59 AM)

Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight

at www.benzinga.com (Fri, 9-Jan 1:52 AM)

Biopharma stocks to see increased M&A activity amid Eli Lilly-Ventyx deal

at seekingalpha.com (Thu, 8-Jan 1:15 PM)

Pfizer collaborating with Boltz to use AI models for drug discovery

at seekingalpha.com (Thu, 8-Jan 9:24 AM)

Berenberg Bank Sticks to Their Hold Rating for Pfizer (PFE)

at www.tipranks.com (Thu, 8-Jan 1:55 AM)

LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze

at www.tipranks.com (Thu, 8-Jan 12:30 AM)

Citi Keeps Their Hold Rating on Pfizer (PFE)

at www.tipranks.com (Wed, 7-Jan 1:26 PM)

Pfizer’s Scottish RSV Maternal Vaccine Study: What Investors Should Watch

at www.tipranks.com (Wed, 7-Jan 11:33 AM)

JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze

at www.tipranks.com (Wed, 7-Jan 10:46 AM)

Patent Cliff Overhang and Uncertain Pipeline Offset Obesity Upside, Justifying Hold on Fairly Valued Pfizer Shares

at www.tipranks.com (Wed, 7-Jan 5:26 AM)

Pfizer Lowers 2026 Revenue Guidance But Reaffirms Profitability Targets Amid R&D Investment

Market Chameleon (Tue, 16-Dec 7:08 AM)

Pfizer Secures Global Rights to Oral GLP-1 Drug Candidate in $2 Billion Collaboration With Fosun Pharma

Market Chameleon (Tue, 9-Dec 7:09 AM)

Pfizer's $7 Billion Metsera Acquisition Strengthens Its Push Into Obesity Treatments

Market Chameleon (Fri, 14-Nov 8:22 AM)

Pfizer Raises 2025 EPS Outlook Despite Revenue Headwinds—Obesity Push and Cost Savings Drive Optimism

Market Chameleon (Tue, 4-Nov 7:21 AM)